Novartis Advances Remibrutinib Toward FDA Approval in Chronic Inducible Urticaria | iPharmaCenter
Does Novartis remibrutinib work for chronic inducible urticaria? Yes, first Phase III success in 3 CIndU types Oral remibrutinib hit primary endpoint vs. placebo at week 12 in RemIND trial, with complete responses in symptomatic dermographism, cold urticaria, and cholinergic urticaria. Rhapsido CIndU approval status Novartis seeks FDA approval for dermographism (most common form of CIndU). Why This Matters First targeted therapy for CIndU, affecting ~29M adults worldwide Sa
Lilly's Taltz + Zepbound Combo Achieves Superior Psoriasis Clearance and Weight Loss in Phase 3b Trial | iPharmaCenter
Eli Lilly shared encouraging early findings from the innovative TOGETHER-PsO trial, testing ixekizumab (Taltz) alongside tirzepatide (Zepbound) against ixekizumab solo in patients facing moderate-to-severe plaque psoriasis plus obesity or excess weight and related health issues. Trial Achieves Dual Goals After 36 weeks, those getting both drugs saw far better outcomes on the main goal, full skin clearing (PASI 100 score) paired with 10%+ body weight drop, outpacing the ixekiz
Amgen’s Uplizna wins European Commission approval for generalized myasthenia gravis | iPharmaCenter
Amgen has secured European Commission clearance for Uplizna (inebilizumab) as an add‑on therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti‑acetylcholine receptor (AChR) or anti‑muscle‑specific tyrosine kinase (MuSK) antibodies. The decision introduces a targeted B‑cell–depleting option that can be given as two loading infusions followed by maintenance dosing twice a year, with the aim of providing sustained disease control alongside existin
GSK’s ultra‑long‑acting IL‑5 biologic Exdensur wins EU approval for severe asthma and CRSwNP | iPharmaCenter
Exdensur (depemokimab), GSK’s new ultra‑long‑acting anti‑IL‑5 biologic, has been granted marketing authorisation by the European Commission for two respiratory indications: severe asthma driven by type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). It is the first biologic in the EU that can be used across respiratory diseases with a twice‑yearly dosing schedule, and the approval is supported by four phase III studies – SWIFT‑1, SWIFT‑2, ANCHOR‑1 and AN
The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter
Get the definitive ranking of the top-selling pharmaceutical drugs by global revenue in 2025. See which blockbusters—from Keytruda to the GLP-1 therapies like Ozempic and Mounjaro—are leading the market and driving record sales in Oncology and Immunology.
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies